Skip to main content
. 2024 Nov 25;15:10213. doi: 10.1038/s41467-024-53223-3

Fig. 8. Acquired plasma ctDNA mutations at disease progression in patients with HER2-positive mCRC treated with T-DXd.

Fig. 8

Acquired refers to patients with acquired mutations detected only at disease progression. Lost refers to patients with mutations detected only at cycle 1, day 1. Maintained refers to patients with mutations at cycle 1, day 1, and at disease progression. bTMB, blood tumor mutational burden; CBOR, confirmed best overall response; ctDNA, circulating tumor DNA; HER2, human epidermal growth factor receptor 2; mCRC, metastatic colorectal cancer; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.